Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccination to Prevent HCC Recurrence
NCT06193733Phase 2Active, not recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jul 2019
- Primary completion
- Feb 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell therapy (Chang Gung Memorial Hospital) in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Started Jul 2019; status: active, not recruiting.
02
Drugs
autologous dendritic cell therapy (Chang Gung Memorial Hospital)
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06193733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193733.